Positive clinical data for PBI-1402 presented at the Annual Congress of the European Hematology Association

    MONTREAL, June 14 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI)
("ProMetic") today presented results on its orally-active PBI-1402 compound in
clinical trial in patients with chemotherapy-induced anemia ("CIA") at the
13th Congress of the European Hematology Association held in Copenhagen,
Denmark this week.
    Dr. Lyne Gagnon, ProMetic's Director R&D, Biology, presented data on
PBI-1402 in a poster entitled "PBI-1402 increases hemoglobin level and red
blood cell count in chemotherapy-induced anemia". Results demonstrated that a
once daily oral treatment of PBI-1402 induces a significant increase in
hemoglobin ("Hb") level, red blood cell ("RBC") count and hematocrit ("Ht") in
CIA patients. Furthermore, results suggest that PBI-1402 can reduce the need
for RBC transfusion, since only 6% of patients in the clinical trial required
    "Subsequent positive data compiled from the 28 patients having completed
the PBI-1402 CIA clinical trial include the fact that 26 of these patients did
not require RBC transfusions while maintaining their full chemotherapy
regimen. This data further supports that PBI-1402's current performance is in
line with the Food and Drug Administration's ("FDA") recommendation of
reducing patient need for RBC transfusions," states Mr. Pierre Laurin,
ProMetic's President and Chief Executive Officer. "Additionally, PBI-1402
offers the added advantage of oral dosing which allows for a convenient
management of anemia without interference with other treatments received by
the CIA patients."
    In the March 13, 2008 briefing document, the FDA's Oncologic Drugs
Advisory Committee emphasized that the primary objective of treating CIA
patients with erythropoiesis-stimulating agents ("ESAs") as being the ability
to reduce the need for RBC transfusions. Approximately 50% of anemic patients
receiving chemotherapy require RBC transfusions, and 20%-25% of patients
treated with ESAs still require RBC transfusions.

    About ProMetic Life Sciences Inc.

    ProMetic Life Sciences Inc. ("ProMetic") (www.prometic.com) is a
biopharmaceutical company specialized in the research, development,
manufacture and marketing of a variety of commercial applications derived from
its proprietary Mimetic Ligand(TM) technology. This technology is used in
large-scale purification of biologics and the elimination of pathogens.
ProMetic is also active in therapeutic drug development with the mission to
bring to market effective, innovative, lower cost, less toxic products for the
treatment of hematology and cancer. Its drug discovery platform is focused on
replacing complex, expensive proteins with synthetic "drug-like" protein
mimetics. Headquartered in Montréal (Canada), ProMetic has R&D facilities in
the U.K., the U.S. and Canada, manufacturing facilities in the U.K. and
business development activities in the US, Europe, Asia and in the

    Forward Looking Statements

    This press release contains forward-looking statements about ProMetic's
objectives, strategies and businesses that involve risks and uncertainties.
These statements are "forward-looking" because they are based on our current
expectations about the markets we operate in and on various estimates and
assumptions. Actual events or results may differ materially from those
anticipated in these forward-looking statements if known or unknown risks
affect our business, or if our estimates or assumptions turn out to be
inaccurate. Such risks and assumptions include, but are not limited to,
ProMetic's ability to develop, manufacture, and successfully commercialize
value-added pharmaceutical products, the availability of funds and resources
to pursue R&D projects, the successful and timely completion of clinical
studies, the ability of ProMetic to take advantage of business opportunities
in the pharmaceutical industry, uncertainties related to the regulatory
process and general changes in economic conditions. You will find a more
detailed assessment of the risks that could cause actual events or results to
materially differ from our current expectations on page 21 of ProMetic's
Annual Information Form for the year ended December 31, 2007, under the
heading "Risk Factors". As a result, we cannot guarantee that any
forward-looking statement will materialize. We assume no obligation to update
any forward-looking statement even if new information becomes available, as a
result of future events or for any other reason, unless required by applicable
securities laws and regulations.

For further information:

For further information: Company Inquiries: Pierre Laurin, President and
CEO, ProMetic Life Sciences Inc., (514) 341-2115, p.laurin@prometic.com; Anne
Leduc, Manager, Investor Relations & Communications, ProMetic Life Sciences
Inc., (514) 341-2115, a.leduc@prometic.com; Dominic Sicotte, Echoes Financial
Network Inc., (514) 842-9551, dsicotte@echoesfinancial.com; Investor
Relations: Bruce Voss, Lippert/Heilshorn & Associates, (310) 691-7100,
BVoss@lhai.com; Kim Golodetz, Lippert/Heilshorn & Associates, (212) 838-3777,
KGolodetz@lhai.com; Media Relations: Jules Abraham, Lippert/Heilshorn &
Associates, (212) 838-3777, JAbraham@lhai.com

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890